Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 83,969 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · derivative · entry 5 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,969 Underlying: Common Stock · 83,969 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 23,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · derivative · entry 4 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,384 Underlying: Common Stock · 23,384 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,543 Underlying: Common Stock · 4,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC |
Fiedler SusanneChief Commercial Officer
|
Tax withholdingCommon Stock | 1,520 | $23.09 | $35,096.80 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,646 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionCommon Stock | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
GrantStock Option (right to buy) · Derivative | 66,793 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · derivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,793 Underlying: Common Stock · 66,793 shares Expires 2033-03-31 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionRestricted Stock Units · Derivative | 7,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,838 Underlying: Common Stock · 7,419 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 2,115 | $23.09 | $48,835.35 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,785 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:21 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 7,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023089 · doc4.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC |
DiMarco KathrynCorporate Controller
|
GrantRestricted Stock Units · Derivative | 25,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · derivative · entry 4 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,510 Underlying: Common Stock · 25,510 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,588 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC |
DiMarco KathrynCorporate Controller
|
Tax withholdingCommon Stock | 1,471 | $23.09 | $33,965.39 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,698 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:21 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 129,770 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023087 · doc4.xml · derivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,770 Underlying: Common Stock · 129,770 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:21 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 36,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023087 · doc4.xml · derivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,139 Underlying: Common Stock · 36,139 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:21 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023087 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,507 Underlying: Common Stock · 7,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:21 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 2,656 | $23.09 | $61,327.04 |
DisclosureSEC source: 0001209191-23-023087 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,803 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:21 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 7,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023087 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC |
Stahler Rachel AChief Information Officer
|
GrantStock Option (right to buy) · Derivative | 70,610 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · derivative · entry 5 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,610 Underlying: Common Stock · 70,610 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC |
Stahler Rachel AChief Information Officer
|
GrantRestricted Stock Units · Derivative | 19,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · derivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,664 Underlying: Common Stock · 19,664 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,157 Underlying: Common Stock · 3,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 1,226 | $23.09 | $28,308.34 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,302 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Ritter Geralyn SHead of Ext. Affairs and ESG
|
GrantStock Option (right to buy) · Derivative | 41,984 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023084 · doc4.xml · derivative · entry 4 Ritter Geralyn S · CIK 0001859678 · Head of Ext. Affairs and ESG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,984 Underlying: Common Stock · 41,984 shares Expires 2033-03-31 F4 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Ritter Geralyn SHead of Ext. Affairs and ESG
|
Exercise / conversionRestricted Stock Units · Derivative | 1,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023084 · doc4.xml · derivative · entry 3 Ritter Geralyn S · CIK 0001859678 · Head of Ext. Affairs and ESG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,817 Underlying: Common Stock · 1,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F3 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Ritter Geralyn SHead of Ext. Affairs and ESG
|
Tax withholdingCommon Stock | 654 | $23.09 | $15,100.86 |
DisclosureSEC source: 0001209191-23-023084 · doc4.xml · nonDerivative · entry 2 Ritter Geralyn S · CIK 0001859678 · Head of Ext. Affairs and ESG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,839 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Ritter Geralyn SHead of Ext. Affairs and ESG
|
Exercise / conversionCommon Stock | 1,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023084 · doc4.xml · nonDerivative · entry 1 Ritter Geralyn S · CIK 0001859678 · Head of Ext. Affairs and ESG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantStock Option (right to buy) · Derivative | 49,618 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023082 · doc4.xml · derivative · entry 4 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,618 Underlying: Common Stock · 49,618 shares Expires 2033-03-31 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 2,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023082 · doc4.xml · derivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,726 Underlying: Common Stock · 2,862 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 981 | $23.09 | $22,651.29 |
DisclosureSEC source: 0001209191-23-023082 · doc4.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,986 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:19 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantCommon Stock | 2,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023082 · doc4.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,967 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantStock Option (right to buy) · Derivative | 83,969 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023081 · doc4.xml · derivative · entry 5 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,969 Underlying: Common Stock · 83,969 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantRestricted Stock Units · Derivative | 23,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023081 · doc4.xml · derivative · entry 4 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,384 Underlying: Common Stock · 23,384 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionRestricted Stock Units · Derivative | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023081 · doc4.xml · derivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,873 Underlying: Common Stock · 3,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 1,122 | $23.09 | $25,906.98 |
DisclosureSEC source: 0001209191-23-023081 · doc4.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,514 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionCommon Stock | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023081 · doc4.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Milligan SandraHead of Research & Development
|
GrantStock Option (right to buy) · Derivative | 104,961 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · derivative · entry 5 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,961 Underlying: Common Stock · 104,961 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Milligan SandraHead of Research & Development
|
GrantRestricted Stock Units · Derivative | 29,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · derivative · entry 4 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,230 Underlying: Common Stock · 29,230 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Milligan SandraHead of Research & Development
|
Exercise / conversionRestricted Stock Units · Derivative | 5,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,928 Underlying: Common Stock · 5,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Milligan SandraHead of Research & Development
|
Tax withholdingCommon Stock | 2,115 | $23.09 | $48,835.35 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,710 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC |
Milligan SandraHead of Research & Development
|
Exercise / conversionCommon Stock | 5,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC |
Falcione AaronChief Human Resources Officer
|
GrantStock Option (right to buy) · Derivative | 72,519 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · derivative · entry 5 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,519 Underlying: Common Stock · 72,519 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC |
Falcione AaronChief Human Resources Officer
|
GrantRestricted Stock Units · Derivative | 20,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · derivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,195 Underlying: Common Stock · 20,195 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,157 Underlying: Common Stock · 3,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 1,226 | $23.09 | $28,308.34 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,139 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:15 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023075 · doc4.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 419,847 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · derivative · entry 5 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,847 Underlying: Common Stock · 419,847 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 116,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · derivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,921 Underlying: Common Stock · 116,921 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,943 Underlying: Common Stock · 21,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 11,895 | $23.09 | $274,655.55 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,495 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.